ArticleOncotarget2017
Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.
Feng-Che Kuan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this paperpooled itcites it